Haruo Inokuchi

Summary

Affiliation: Aichi Cancer Center
Country: Japan

Publications

  1. ncbi Retrospective analysis of postoperative radiotherapy for node-negative cervical carcinoma with stage IB-IIB disease
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center, Nagoya, Japan
    Jpn J Clin Oncol 32:255-61. 2002
  2. ncbi Retrospective analysis of definitive radiotherapy for patients with superficial esophageal carcinoma: Consideration of the optimal treatment method with a focus on late morbidity
    Takeshi Kodaira
    Department of Therapeutic Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
    Radiother Oncol 95:234-9. 2010
  3. ncbi Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical tomotherapy
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    Int J Radiat Oncol Biol Phys 73:1129-34. 2009
  4. ncbi Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer
    Takeshi Kodaira
    Department of Therapeutic Radiation Oncology, Aichi Cancer Center Hospital, 464 8681 Nagoya, Aichi, Japan
    Anticancer Res 26:2265-8. 2006
  5. ncbi Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma
    Takeshi Kodaira
    Department of Therapeutic Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Anticancer Res 26:471-8. 2006
  6. ncbi Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications
    Takeshi Kodaira
    Department of Therapeutic Radiation Oncology, Aichi Cancer Center, Chikusa ku, 464 8681 Nagoya, Aichi, Japan
    Jpn J Clin Oncol 35:173-6. 2005
  7. ncbi Comparison of prognostic value of MRI and FIGO stage among patients with cervical carcinoma treated with radiotherapy
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center, Aichi, Japan
    Int J Radiat Oncol Biol Phys 56:769-77. 2003
  8. ncbi Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors
    Tatsuya Nakamura
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Jpn J Clin Oncol 38:803-9. 2008
  9. ncbi Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection
    Haruo Inokuchi
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Int J Radiat Oncol Biol Phys 79:747-55. 2011
  10. ncbi Prospective study of alternating chemoradiotherapy consisting of extended-field dynamic conformational radiotherapy and systemic chemotherapy using 5-FU and nedaplatin for patients in high-risk group with cervical carcinoma
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    Int J Radiat Oncol Biol Phys 73:251-8. 2009

Collaborators

Detail Information

Publications16

  1. ncbi Retrospective analysis of postoperative radiotherapy for node-negative cervical carcinoma with stage IB-IIB disease
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center, Nagoya, Japan
    Jpn J Clin Oncol 32:255-61. 2002
    ..We performed retrospective analysis to evaluate the outcomes of postoperative radiotherapy for patients with cervical carcinoma without lymph node metastasis...
  2. ncbi Retrospective analysis of definitive radiotherapy for patients with superficial esophageal carcinoma: Consideration of the optimal treatment method with a focus on late morbidity
    Takeshi Kodaira
    Department of Therapeutic Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
    Radiother Oncol 95:234-9. 2010
    ..To evaluate the clinical efficacy of definitive radiotherapy for patients with superficial esophageal cancer...
  3. ncbi Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical tomotherapy
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    Int J Radiat Oncol Biol Phys 73:1129-34. 2009
    ..To assess the feasibility of helical tomotherapy (HT) for patients with nasopharyngeal carcinoma...
  4. ncbi Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer
    Takeshi Kodaira
    Department of Therapeutic Radiation Oncology, Aichi Cancer Center Hospital, 464 8681 Nagoya, Aichi, Japan
    Anticancer Res 26:2265-8. 2006
    ..A phase I study of chemotherapy was planned with S-1 and nedaplatin to find the optimal dose for patients with recurrent head and neck cancer...
  5. ncbi Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma
    Takeshi Kodaira
    Department of Therapeutic Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Anticancer Res 26:471-8. 2006
    ..To assess the efficacy and feasibility of alternating chemoradiotherapy for esophageal cancer...
  6. ncbi Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications
    Takeshi Kodaira
    Department of Therapeutic Radiation Oncology, Aichi Cancer Center, Chikusa ku, 464 8681 Nagoya, Aichi, Japan
    Jpn J Clin Oncol 35:173-6. 2005
    ..We planned a phase I study of radiotherapy combined with weekly docetaxel for elderly patients or patients with complications to find out the optimal dose...
  7. ncbi Comparison of prognostic value of MRI and FIGO stage among patients with cervical carcinoma treated with radiotherapy
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center, Aichi, Japan
    Int J Radiat Oncol Biol Phys 56:769-77. 2003
    ..To compare the efficacy of MRI and FIGO stage, we performed retrospective multicenter analysis of patients with Stage II-III disease treated with radiation alone...
  8. ncbi Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors
    Tatsuya Nakamura
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Jpn J Clin Oncol 38:803-9. 2008
    ..To evaluate the treatment outcome of patients with locally recurrent nasopharyngeal carcinoma (NPC) treated with re-irradiation and chemotherapy...
  9. ncbi Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection
    Haruo Inokuchi
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Int J Radiat Oncol Biol Phys 79:747-55. 2011
    ..To evaluate the clinical effectiveness of pretreatment [18F] fluoro-2-deoxy-D-glucose-positron emission tomography for head-and-neck squamous cell carcinoma patients with nodal metastasis treated with chemoradiotherapy...
  10. ncbi Prospective study of alternating chemoradiotherapy consisting of extended-field dynamic conformational radiotherapy and systemic chemotherapy using 5-FU and nedaplatin for patients in high-risk group with cervical carcinoma
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    Int J Radiat Oncol Biol Phys 73:251-8. 2009
    ..To assess the efficacy of alternating chemoradiotherapy combined with extended-field conformal radiotherapy for patients with high-risk cervical cancer...
  11. ncbi The impact of radiation dose and fractionation on outcomes for limited-stage small-cell lung cancer
    Natsuo Tomita
    Department of Radiation Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusaku, Nagoya 464 8681, Japan
    Int J Radiat Oncol Biol Phys 76:1121-6. 2010
    ....
  12. ncbi Determination of the irradiation field for clinical T1-T3N0M0 thoracic/abdominal esophageal cancer based on the postoperative pathological results
    Tatsuya Nakamura
    Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 7 172, Yatsuyamada, Koriyama City, Fukushima 963 8052, Japan
    Jpn J Clin Oncol 39:86-91. 2009
    ..In this study, the extent of the irradiation field for clinical stage T1-3N0M0 esophageal cancer was determined based on the postoperative pathological results...
  13. ncbi Dynamic conformal arc radiotherapy with rectum hollow-out technique for localized prostate cancer
    Natsuo Tomita
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Radiother Oncol 90:346-52. 2009
    ..To report the feasibility of dynamic conformal arc radiotherapy with rectum hollow-out technique (DCAT-HO) for localized prostate cancer...
  14. ncbi Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy
    Tatsuya Nakamura
    Radiation Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusaku, Nagoya 464 8681, Japan
    Lung 186:91-6. 2008
    ..Patients whose primary tumor is located in the superior lobe appear to have a better clinical outcome...
  15. ncbi Treatment outcomes of definitive chemoradiotherapy for patients with hypopharyngeal cancer
    Rie Nakahara
    Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    J Radiat Res 53:906-15. 2012
    ..Second primary cancer may have a clinical impact on the outcome for HPC patients, and special care should be taken when screening at follow-up...
  16. ncbi Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer
    Tatsuya Nakamura
    Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 7 172 Yatsuyamada, Koriyama, Fukushima 963 8052, Japan
    Head Neck 34:1634-9. 2012
    ..We planned a phase I study of weekly arterial infusion of docetaxel and cisplatin via a superficial temporal artery for recurrent head and neck cancer to determine the optimal dose...